BR112013017001A2 - composição farmacêutica contendo l-dna - Google Patents
composição farmacêutica contendo l-dnaInfo
- Publication number
- BR112013017001A2 BR112013017001A2 BR112013017001A BR112013017001A BR112013017001A2 BR 112013017001 A2 BR112013017001 A2 BR 112013017001A2 BR 112013017001 A BR112013017001 A BR 112013017001A BR 112013017001 A BR112013017001 A BR 112013017001A BR 112013017001 A2 BR112013017001 A2 BR 112013017001A2
- Authority
- BR
- Brazil
- Prior art keywords
- dna
- pharmaceutical composition
- rna
- composition containing
- cleavage
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 238000007086 side reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
composição farmacêutica contendo l-dna a invenção refere-se à utilização de um l-dna, que é capaz de ligação a um l-rna, em particular, numa reação de anti-sentido e que é, opcipnalmente, capaz de clivagem do l-rna na região de uma sequência alvo do l-rna para produzir uma composiçao farmacêutica para o tratamento de reações fisiológicas colaterais indesejáveis causadas pela administração de uma mólecula terapêutica contendo o referido l-rna. alternativamente, o l-dna também pode ser utilizado para a clivagem de um rna ou dna alvo endógeno
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010056610A DE102010056610A1 (de) | 2010-12-31 | 2010-12-31 | Pharmazeutische Zusammensetzung enthaltend L-DNA |
| PCT/DE2012/000008 WO2012089207A2 (de) | 2010-12-31 | 2012-01-02 | Pharmazeutische zusammensetzung enthaltend l-dna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013017001A2 true BR112013017001A2 (pt) | 2016-09-20 |
Family
ID=45999500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013017001A BR112013017001A2 (pt) | 2010-12-31 | 2012-01-02 | composição farmacêutica contendo l-dna |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130345290A1 (pt) |
| EP (1) | EP2668275A2 (pt) |
| JP (1) | JP2014504589A (pt) |
| KR (1) | KR20140043052A (pt) |
| CN (1) | CN103492571A (pt) |
| AU (1) | AU2012203994A1 (pt) |
| BR (1) | BR112013017001A2 (pt) |
| CA (1) | CA2850863A1 (pt) |
| DE (1) | DE102010056610A1 (pt) |
| MX (1) | MX2013007543A (pt) |
| RU (1) | RU2013135647A (pt) |
| WO (1) | WO2012089207A2 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009058769A1 (de) | 2009-12-16 | 2011-06-22 | MagForce Nanotechnologies AG, 10589 | Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung |
| US9983565B2 (en) * | 2015-03-27 | 2018-05-29 | Intel Corporation | Technologies for bio-chemically controlling operation of a machine |
| CN105274196A (zh) * | 2015-04-01 | 2016-01-27 | 湖南大学 | 一种基于l型脱氧核酶生物体系中金属离子的检测试剂盒、检测方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59708838D1 (de) * | 1996-08-30 | 2003-01-09 | Jens Peter Fuerste | Spiegelselektion und spiegelevolution von nucleinsäuren |
| DE19800899A1 (de) * | 1998-01-13 | 1999-07-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Oligoliganden mit Bindungsvermögen etc. |
| DE10020275A1 (de) * | 2000-04-25 | 2001-10-31 | Manfred Schneider | Enantiomere Bausteine der 2-Deoxy-L-Ribose und 2-Deoxy-D-Ribose, Verfahren zu ihrer Herstellung sowie Verwendung zur Synthese von natürlichen und nicht natürliche L- und D-Nucleinsäuren, L- und D- konfigurierten Oligonucleotiden, L- und D-konfigurierter DNA und davon abgeleiteten pharmazeutischen Wirkstoffen |
| ATE452655T1 (de) * | 2001-06-10 | 2010-01-15 | Noxxon Pharma Ag | Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung |
| US20030219422A1 (en) * | 2001-11-15 | 2003-11-27 | Noxxon Pharma Ag | Allosteric ribozymes and uses thereof |
| US7101991B2 (en) * | 2002-10-02 | 2006-09-05 | The University Of British Columbia | Compositions and methods for treatment of prostate and other cancers |
| DE10346487A1 (de) * | 2003-10-02 | 2005-05-12 | Transmit Technologietransfer | Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels |
| CN101217967B (zh) * | 2005-05-04 | 2014-09-10 | 诺松制药股份公司 | 镜像异构体的新用途 |
| EP2111449B1 (en) | 2007-01-16 | 2012-03-07 | Yissum Research Development Company of the Hebrew University of Jerusalem | H19 silencing nucleic acid agents for treating rheumatoid arthritis |
| EP2393504B1 (de) | 2009-02-06 | 2013-06-05 | Freie Universität Berlin | Ein l-ribozym enthaltende pharmazeutische zusammensetzung zur behandlung von nebenwirkungen durch gabe von spiegelmeren |
-
2010
- 2010-12-31 DE DE102010056610A patent/DE102010056610A1/de not_active Withdrawn
-
2012
- 2012-01-02 RU RU2013135647/10A patent/RU2013135647A/ru not_active Application Discontinuation
- 2012-01-02 EP EP12716194.1A patent/EP2668275A2/de not_active Withdrawn
- 2012-01-02 BR BR112013017001A patent/BR112013017001A2/pt not_active IP Right Cessation
- 2012-01-02 CN CN201280011039.2A patent/CN103492571A/zh active Pending
- 2012-01-02 JP JP2013546589A patent/JP2014504589A/ja active Pending
- 2012-01-02 KR KR1020137020401A patent/KR20140043052A/ko not_active Application Discontinuation
- 2012-01-02 US US13/977,088 patent/US20130345290A1/en not_active Abandoned
- 2012-01-02 MX MX2013007543A patent/MX2013007543A/es not_active Application Discontinuation
- 2012-01-02 AU AU2012203994A patent/AU2012203994A1/en not_active Abandoned
- 2012-01-02 CA CA2850863A patent/CA2850863A1/en not_active Abandoned
- 2012-01-02 WO PCT/DE2012/000008 patent/WO2012089207A2/de active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012089207A3 (de) | 2012-10-04 |
| CN103492571A (zh) | 2014-01-01 |
| DE102010056610A1 (de) | 2012-07-05 |
| EP2668275A2 (de) | 2013-12-04 |
| RU2013135647A (ru) | 2015-02-10 |
| MX2013007543A (es) | 2014-04-30 |
| AU2012203994A1 (en) | 2013-08-22 |
| JP2014504589A (ja) | 2014-02-24 |
| WO2012089207A2 (de) | 2012-07-05 |
| KR20140043052A (ko) | 2014-04-08 |
| CA2850863A1 (en) | 2012-05-07 |
| US20130345290A1 (en) | 2013-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013020273A2 (pt) | oligonucleotídeos antissenso | |
| BR112015008708A2 (pt) | composição para clivagem de dna alvo compreendendo um rna guia específico para o dna alvo e ácido nucleico que codifica proteína cas ou proteína cas e uso da mesma | |
| EA201490993A1 (ru) | МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи | |
| BR112018075479A2 (pt) | portadores híbridos para carga de ácido nucleico | |
| BR112015004747A2 (pt) | moléculas oligonucleotídicas de fita dupla para p53 e métodos de uso das mesmas | |
| BR112014016165A2 (pt) | compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido | |
| BR112012027034A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| BR112015022998A2 (pt) | composições melhoradas para o tratamento de distrofia muscular | |
| EA201591281A1 (ru) | Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы | |
| BR112014019431A8 (pt) | Método compartimentalizado de distribuição de ácido nucleico e composições e usos desses | |
| EA201070421A1 (ru) | Микрорибонуклеиновые кислоты | |
| BR112015012536A2 (pt) | tratamento de câncer com inibidores heterocíclicos da glutaminase | |
| BR112014009415A2 (pt) | inibidores de arginase e suas aplicações terapêuticas | |
| BR112013009029A2 (pt) | métodos e composições para inibição de polimerase | |
| BR112015009624A2 (pt) | inibidores de tirosina cinase de bruton | |
| BR112015005227A2 (pt) | inibidores de glicosilceramida sintase | |
| BR112015011244A8 (pt) | análogos de compstatina de reação celular, ação longa ou direcionados e composições e métodos relacionados | |
| BR112014021612A2 (pt) | composições e métodos para modulação da expressão de atxn3 | |
| BR112012011195A2 (pt) | Oligonucleotídeo antissentido, composição e respectivo uso. | |
| MD20150043A2 (ro) | Inhibitori ai histon-demetilazelor | |
| BR112015014987A2 (pt) | Aprimoradas composições que pulam éxon para o tratamento da distrofia muscular | |
| BR112014030743A2 (pt) | inibidores de neprilisina | |
| BR112014015851A2 (pt) | proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17 | |
| BR112015012051A2 (pt) | composições e métodos para modulação de expressão de fgfr3 | |
| BR112013028816A2 (pt) | "análogos de compstatina, composição que os compreende e uso dos mesmos". |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |